Trial
NCT04239014
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Phase IIWITHDRAWNEFFICACY/FUTILITYConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
Parexel
Condition
Ovarian Cancer
Intervention
Olaparib
Why stopped
Sponsor made the decision to terminate the DUETTE study based on the interim analysis of the VIOLETTE study (NCT03330847) investigating the combination of ceralasertib and Olaparib, where study closure was recommended due to insufficient efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-10